Linked e-resources
Details
Table of Contents
Intro
Preface
Contents
Part I: Current Topics in Epidemiology and Examinations of Pancreatic Cancer and Cholangiocarcinoma
1: Risk Factors for Pancreatic Cancer and Cholangiocarcinoma
1.1 Risk Factors for Pancreatic Cancer
1.1.1 Introduction
1.1.2 Genetic Factors
1.1.3 Pancreatic Disorders (Cystic Lesions and Chronic Pancreatitis)
1.1.4 Epidemiological Factors
1.1.5 Microbiome
1.1.6 Discussion
1.2 Risk Factors for Cholangiocarcinoma
1.2.1 Introduction
1.2.2 Microbiome (Infectious Diseases)
1.2.3 Genetic Factors
1.2.4 Pancreatobiliary and Inflammatory Disorders
1.2.5 Epidemiological Factors
1.2.6 Discussion
References
2: Detection Strategies and Examination of Early Pancreatic Cancer
2.1 Introduction
2.2 Clinical Features and Image Findings of Early-Stage PC
2.3 Cytological Diagnosis of Early-Stage PC
2.4 Pathological Features of Early-Stage PC
2.5 Statements and Detection Strategies of Early-Stage PC in Japan
2.6 Collaborations Between Specialists and General Practitioners for Early-Stage PC in Japan
References
3: Biomarkers for Pancreatic Cancer and Cholangiocarcinoma
3.1 Introduction
3.2 Currently Used Biomarkers for PDAC and CCA
3.3 Other Protein Markers for PDAC and CCA
3.4 Circulating Tumor Cells
3.5 Extracellular Vesicles
3.6 Biomarker-Based Selection of Targeted Therapies
3.7 Conclusion and Future Perspectives
References
4: Recent Advances of Precision Medicine in Pancreatic Cancer and Cholangiocarcinoma
4.1 Introduction
4.2 Features of Two Reimbursed CGP Tests
4.3 Required Tissue Samples
4.4 Liquid Biopsy
4.5 Eligible Patients for CGP Test and Optimal Timing of Its Application
4.6 Clinical Benefit of CGP Tests in Pancreatic Cancer
4.7 Clinical Benefit of CGP Tests in Biliary Tract Cancer
References
Part II: Anti-cancer Treatments for Pancreatic Cancer
5: Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
5.1 Introduction
5.2 Metastatic Pancreatic Cancer
5.2.1 FOLFIRINOX
5.2.2 Gemcitabine Plus Nab-Paclitaxel
5.2.3 Selection Between FOLFIRINOX and Gemcitabine Plus Nab-Paclitaxel
5.2.4 Intraperitoneal Chemotherapy in Patients with Peritoneal Dissemination
5.3 Locally Advanced Pancreatic Cancer
5.4 The Role of Monotherapy
5.5 Second-Line Chemotherapy
5.6 Future Perspective
References
6: Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer
6.1 Introduction
6.2 Preoperative Estimation for Surgical Resectability
6.3 Potentially Resectable Tumors
6.4 Prospective Studies for NAT and Adjuvant Therapy
6.5 Optimal Agent or Regimens for NAT for Potentially Resectable PA
Preface
Contents
Part I: Current Topics in Epidemiology and Examinations of Pancreatic Cancer and Cholangiocarcinoma
1: Risk Factors for Pancreatic Cancer and Cholangiocarcinoma
1.1 Risk Factors for Pancreatic Cancer
1.1.1 Introduction
1.1.2 Genetic Factors
1.1.3 Pancreatic Disorders (Cystic Lesions and Chronic Pancreatitis)
1.1.4 Epidemiological Factors
1.1.5 Microbiome
1.1.6 Discussion
1.2 Risk Factors for Cholangiocarcinoma
1.2.1 Introduction
1.2.2 Microbiome (Infectious Diseases)
1.2.3 Genetic Factors
1.2.4 Pancreatobiliary and Inflammatory Disorders
1.2.5 Epidemiological Factors
1.2.6 Discussion
References
2: Detection Strategies and Examination of Early Pancreatic Cancer
2.1 Introduction
2.2 Clinical Features and Image Findings of Early-Stage PC
2.3 Cytological Diagnosis of Early-Stage PC
2.4 Pathological Features of Early-Stage PC
2.5 Statements and Detection Strategies of Early-Stage PC in Japan
2.6 Collaborations Between Specialists and General Practitioners for Early-Stage PC in Japan
References
3: Biomarkers for Pancreatic Cancer and Cholangiocarcinoma
3.1 Introduction
3.2 Currently Used Biomarkers for PDAC and CCA
3.3 Other Protein Markers for PDAC and CCA
3.4 Circulating Tumor Cells
3.5 Extracellular Vesicles
3.6 Biomarker-Based Selection of Targeted Therapies
3.7 Conclusion and Future Perspectives
References
4: Recent Advances of Precision Medicine in Pancreatic Cancer and Cholangiocarcinoma
4.1 Introduction
4.2 Features of Two Reimbursed CGP Tests
4.3 Required Tissue Samples
4.4 Liquid Biopsy
4.5 Eligible Patients for CGP Test and Optimal Timing of Its Application
4.6 Clinical Benefit of CGP Tests in Pancreatic Cancer
4.7 Clinical Benefit of CGP Tests in Biliary Tract Cancer
References
Part II: Anti-cancer Treatments for Pancreatic Cancer
5: Chemotherapy for Locally Advanced and Metastatic Pancreatic Cancer
5.1 Introduction
5.2 Metastatic Pancreatic Cancer
5.2.1 FOLFIRINOX
5.2.2 Gemcitabine Plus Nab-Paclitaxel
5.2.3 Selection Between FOLFIRINOX and Gemcitabine Plus Nab-Paclitaxel
5.2.4 Intraperitoneal Chemotherapy in Patients with Peritoneal Dissemination
5.3 Locally Advanced Pancreatic Cancer
5.4 The Role of Monotherapy
5.5 Second-Line Chemotherapy
5.6 Future Perspective
References
6: Neoadjuvant Therapy for Resectable and Borderline Resectable Pancreatic Cancer
6.1 Introduction
6.2 Preoperative Estimation for Surgical Resectability
6.3 Potentially Resectable Tumors
6.4 Prospective Studies for NAT and Adjuvant Therapy
6.5 Optimal Agent or Regimens for NAT for Potentially Resectable PA